8/25/21 16:16 | 8/24/21 | CYCC | Cyclacel Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | NJ | D | | P | 5 | 5.00 | 0 | 1 | 42 | 3 | D | | | | | | | | | | | | | | |
8/2/19 16:12 | 8/2/19 | LXRX | Lexicon Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | TX | D | | P | 28 | 1.18 | 0 | 24 | 85 | 52 | D | | | | | | | | | | | | | | |
9/18/17 06:36 | 9/15/17 | LXRX | Lexicon Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | TX | D | | P | 13 | 12.50 | 0 | 1 | 4 | 26 | D | | | | | | | | | | | | | | |
11/20/14 16:24 | 11/20/14 | CYCC | Cyclacel Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | NJ | D | | P | 9 | 3.00 | 0 | 3 | New | 3 | D | -39 | -32 | -5 | -6 | 6 | -12 | -8 | -2 | 0 | 2 | -77 | -74 | -73 | -81 |
5/11/11 16:51 | 5/10/11 | CADX | Cadence Pharmaceuticals Inc | | Health | Drug | Pharmaceutical Preparations | Barker Sam L | CA | D | | P | 63 | 7.04 | 4 | 9 | 82 | 20 | D | -34 | -20 | -9 | 1 | -19 | -10 | -14 | -7 | 8 | 5 | 27 | 6 | -29 | |
10/26/09 16:15 | 10/22/09 | LXRX | Lexicon Pharmaceuticals, Inc./de | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | TX | D | | P | 30 | 1.56 | 0 | 19 | 40 | 66 | D | -60 | 12 | 55 | 4 | -4 | -17 | 1 | -4 | 1 | -14 | 5 | 15 | -1 | 18 |
4/22/08 16:34 | 4/18/08 | LXRX | Lexicon Pharmaceuticals, Inc./de | DE | Health | Drug | Pharmaceutical Preparations | Barker Sam L | TX | D | | P | 79 | 1.96 | 0 | 40 | 571 | 47 | D | -61 | -41 | -43 | -21 | 61 | -3 | 8 | 18 | 6 | 0 | 4 | 2 | -41 | -48 |
3/19/08 19:44 | 3/17/08 | CADX | Cadence Pharmaceuticals Inc | | Health | Drug | Pharmaceutical Preparations | Barker Sam L | CA | D | | P | 58 | 5.25 | 1 | 11 | New | 11 | M | | -60 | -55 | -57 | 6 | 3 | 16 | 2 | -2 | 0 | 8 | 5 | 66 | 39 |
2/1/08 11:00 | 1/25/08 | AGIX | Atherogenics Inc | GA | Health | Drug | Pharmaceutical Preparations | Barker Sam L | GA | D | | P | 10 | 0.3900 | 0 | 25 | 999% | 26 | M | | | | | | | | | | | | | | |